Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | DNTT | P04053 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868042 | 0.91 | MAPT (0.36) | NAAACYP1A2MAPTTLR4EPHX2 | |
| SCHEMBL4867339 | 0.80 | NAAA (0.34) | NAAACYP1A2MAPTTLR4EPHX2 | |
| SCHEMBL23533298 | 0.79 | ALDH1A1 (0.40) | CYP1A2POLBHPGDALDH1A1ALOX5 | |
| SCHEMBL8531001 | 0.76 | APLNR (0.39) | MAPTALDH1A1 | |
| SCHEMBL8774464 | 0.76 | MAPT (0.38) | CYP1A2MAPTEPHX2ALDH1A1 | |
| SCHEMBL4868091 | 0.75 | CYP3A4 (0.41) | CYP1A2ALDH1A1LMNAMAPK1 | |
| SCHEMBL23533404 | 0.73 | ALOX5 (0.42) | CYP1A2MAPTALDH1A1ALOX5HTT | |
| SCHEMBL6059827 | 0.72 | ALDH1A1 (0.40) | ALDH1A1EPHX1MAPK1 | |
| SCHEMBL8774500 | 0.72 | ALOX5 (0.44) | ALDH1A1ALOX5 | |
| SCHEMBL11340566 | 0.72 | LMNA (0.40) | MAPTPOLBHPGDALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | NAAA 935/4885CYP1A2 4681/4885MAPT 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.